Details for the study
Brief Title
Impact of Continuous Positive Airway Pressure (CPAP) Therapy on Outcomes in Patients Undergoing Coronary Revascularization
Official Title
Impact of Continuous Positive Airway Pressure Therapy on Outcomes in Patients Undergoing Coronary Revascularization
Brief Summary
Investigators assume that continuous positive airway pressure (CPAP) therapy can reduce the<br /> mortality, stroke rate and secondary coronary surgery in CAD with obstructive sleep apnea<br /> (OSA) patients after percutaneous coronary intervention (PCI) or coronary artery bypass<br /> grafting (CABA) during postoperative follow-up of 3 years.
Detailed Description
Investigators observe whether continuous positive airway pressure (CPAP) therapy can reduce
the mortality, stroke rate and secondary coronary surgery in CAD with OSA patients after
percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABA) during
postoperative follow-up of 3 years. During the 3 years, we randomize all enrolled patients to
2 groups separately beginning CPAP or no-CPAP intervention after sleep monitoring. Guidance
for all patients during follow-up 1 week, 2 week, 1 month, 3 month. The follow-up procedure
includes clinical assessments at three months, six months, one year, two and three years
respectively.The primary outcome variables are prospectively being documented and are not
subject to observer bias.Baseline comorbidity data, results of the sleep recordings,
compliance with CPAP device, scores of the questionnaires as well as results of the blood
analysis are performed and/or documented consecutively in separate files by research
personnel blinded to the allocation of the study groups and/or unaware of the results of the
concomitant outcomes.
Study Criteria
Inclusion Criteria:
- Angiography confirmed coronary heart disease (CHD) patients
- Underwent PCI or coronary artery bypass graft (CABG) in recent the week
- Signed informed consent
- Mild-to-moderate OSA（5≤AHI≤100)
Exclusion Criteria:
- OSA patients who has already started treatment
- Patients presenting mainly central apnea (≥ 50%)
- Respiratory insufficiency patients
